Zobrazeno 1 - 10
of 82
pro vyhledávání: '"Ehud Ur"'
Autor:
Laurence Kennedy, Andrea Giustina, Asi Haviv, Peter J Trainer, William H. Ludlam, Artak Labadzhyan, Gary Patou, Marek Bolanowski, Maria Fleseriu, Shlomo Melmed, Nienke R. Biermasz, Murray B. Gordon, Susan L. Samson, Lisa B. Nachtigall, Mark E. Molitch, Ehud Ur, Christian J. Strasburger
Publikováno v:
The Journal of Clinical Endocrinology and Metabolism
Journal of Clinical Endocrinology and Metabolism, 105(10), e3785-e3797. ENDOCRINE SOC
Journal of Clinical Endocrinology and Metabolism, 105(10), e3785-e3797. ENDOCRINE SOC
Purpose The phase 3 CHIASMA OPTIMAL trial (NCT03252353) evaluated efficacy and safety of oral octreotide capsules (OOCs) in patients with acromegaly who previously demonstrated biochemical control while receiving injectable somatostatin receptor liga
Autor:
Ehud Ur, Paul Atkins
Publikováno v:
Endocrine research. 45(4)
To present a case series of primary and immunotherapy-related secondary hypophysitis.A single-center retrospective chart review was performed at the University of British Columbia, Vancouver, Canada. Eleven cases of primary hypophysitis and 2 cases o
Autor:
Gary Patou, Christian J. Strasburger, Mark E. Molitch, Waligorska Agata Baldys, Shlomo Melmed, William H. Ludlam, Nienke Biermasz, Mojca Jensterle, Ehud Ur, Maria Fleseriu, Asi Haviv, Laurence Kennedy, Susan L. Samson, Lisa B. Nachtigall
Publikováno v:
Endocrine Abstracts.
Autor:
Lisa B. Nachtigall, Maria Fleseriu, Susan L. Samson, Shlomo Melmed, William H. Ludlam, Gary Patou, Ehud Ur, Asi Haviv, Christian J. Strasburger, Nienke R. Biermasz, Yossi Gilgun-Sherki, Laurence Kennedy
Publikováno v:
Journal of the Endocrine Society
Background: In clinical practice, most patients responding to injectable somatostatin receptor ligands exhibit IGF-I variability around the upper limit of normal (ULN) during long-term follow up. These fluctuations are thought to result from various
Publikováno v:
Clinical endocrinology. 92(5)
Autor:
Ehud Ur, Hadar Shalev, Tali Shafat, Yisrael Parmet, Yonatan Serlin, Jaime Levy, Marina Shneck, Boris Knyazer, Alon Friedman, Aaron Winter
Publikováno v:
Psychoneuroendocrinology. 67:163-170
Diabetic retinopathy (DR) is a common vasculopathy categorized as either non-proliferative (NPDR) or proliferative (PDR),characterized by dysfunctional blood-retinal barrier (BRB) and diagnosed using fluorescein angiography (FA). Since the BRB is sim
Autor:
Agnieszka Dorota Barts, J. Connors, Tom Elliott, Sandra Sirrs, Ehud Ur, Marshall Dahl, S. Stafford, David M. Thompson, D. Harris, T. Keane, Jason M. Kong
Publikováno v:
Current Oncology
Volume 20
Issue 6
Pages 1499-538
Volume 20
Issue 6
Pages 1499-538
Patients with cancer are often treated with glucocorticoids (gcs) as part of therapy, which may cause hyperglycemia. We sought to define the prevalence of, and risk factors for, hyperglycemia in this setting. Adult patients taking gc as part of thera
Autor:
Ehud Ur, Todd J. Anderson, Glen J. Pearson, Robert A. Hegele, G.B. John Mancini, Patrick Couture, Gordon A. Francis, Richard Ward, Jacques Genest, André C. Carpentier, Eva Lonn, Jean Grégoire, Gillian M. Yates, James A. Stone, Milan Gupta, Dominic S. Ng, Ruth McPherson, Lawrence A. Leiter, Steven A. Grover, Robert Dufour, David C.W. Lau, Paul Poirier
Publikováno v:
Canadian Journal of Cardiology. 29:151-167
Many developments have occurred since the publication of the widely-used 2009 Canadian Cardiovascular Society (CCS) Dyslipidemia guidelines. Here, we present an updated version of the guidelines, incorporating new recommendations based on recent find
Autor:
Kathryn Camelon, Stewart B. Harris, Hwee Teoh, David C.W. Lau, Ehud Ur, Rémi Rabasa-Lhoret, Richard E. Gilbert, Philip A. McFarlane, Lawrence A. Leiter
Publikováno v:
Canadian Journal of Diabetes. 36:320-326
Cardiometabolic risk (CMR) refers to the collective consideration of traditional and emerging risk factors that amplify the potential of developing atherogenic cardiovascular disease, as well as the emergence of type 2 diabetes mellitus. Cumulative d
Publikováno v:
Scopus-Elsevier
Recent data have suggested that adipocytes synthesize and secrete a 16 kDa peptide which acts centrally to regulate weight gain by suppressing appetite and activating the sympathetic nervous system. To exert such effects, it may function as an endoge
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e610162c1c98c29af853654581d7a7b0
https://doi.org/10.1097/00001756-199703240-00014
https://doi.org/10.1097/00001756-199703240-00014